Introduction {#s1}
============

Fabry disease (FD) is an X-chromosome linked hereditary disease that belongs to the group of lysosomal storage disorders. It is caused by loss of function mutations in the lysosomal α-galactosidase A (α-Gal A) gene that result in defective glycolipid degradation, and subsequent accumulation of globotriaosylceramide (Gb3) in different tissues, including vascular endothelial cells and neurons (Desnick et al., [@B15]; Gal et al., [@B22]; Saito et al., [@B61]; Bangari et al., [@B2]). Incidence rates for FD span from 1:37′000 for the classical phenotype to 1:3′100 for a late-onset disease variant, with males being more affected than females (Spada et al., [@B65]; Mechtler et al., [@B49]). Nevertheless, also heterozygous females show variable expression of α-Gal A caused by random X-inactivation, which leads to major organ involvement (Wilcox et al., [@B74]). One of the earliest symptoms of FD is small-fiber neuropathy, which leads to pain attacks already in childhood and is associated with accumulation of Gb3 in sensory neurons of dorsal root ganglia (DRG) (Germain, [@B23]; Bangari et al., [@B2]). In addition to neuronal accumulation in the peripheral nervous system, Gb3 deposits are also found in neurons and other cell types of the central nervous system (Khanna et al., [@B37]; Tuttolomondo et al., [@B70],[@B71]). Often, those glycolipid deposits lead to alterations in cerebral vessels and the formation of microstructural damage (i.e., microbleeds) in different brain regions (Tagliavini et al., [@B67]; Reisin et al., [@B60]; Paavilainen et al., [@B53]; Kono et al., [@B39]). In line with these pathologies, different forms of cognitive deficits have been reported in FD patients, spanning from higher prevalence of depression and anxiety to impairment of information processing and attention (Schermuly et al., [@B63]; Bolsover et al., [@B8]; Sigmundsdottir et al., [@B64]), as well as impaired long-term verbal memory (Cocozza et al., [@B11]). These are reflected to some extent in a transgenic FD mouse model which shows increased anxiety-like behavior (Hofmann et al., [@B31]).

In a recent microarray profiling study of DRGs, we provide the first report on changed gene expression in neuronal tissue from a mouse line with a null mutation of α-Gal A modeling FD (Kummer et al., [@B40]). Besides the identification of numerous regulated genes, enriched pathways are implicated in general neuronal dysfunction, for example G-protein coupled receptor activity and neuropeptide signaling that might affect excitability and neuronal activation in FD (Kummer et al., [@B40]). The above mentioned cognitive deficits seen in FD patients and mice may be related to such changes in neuronal excitability or compromised receptor activity in higher brain regions, most probably in the prefrontal cortex (PFC), as the major deficits reported from FD patients refer to attention and executive functioning.

We therefore set out to explore neuronal gene expression changes associated with the loss of function of α-Gal A in a particularly important brain area and link it to the reported cognitive deficits, by performing mRNA microarray expression profiling of PFC tissue samples from adult male α-Gal A^(−/0)^ mice, followed by qPCR validation and in depth bioinformatics analyses of protein-protein interactions and pathways.

Methods {#s2}
=======

Animals
-------

Male α-galactosidase A^(−/0)^ (α-Gal A^(−/0)^; background C57BL/6; kindly provided by Dr. A. Kulkarni, National Institute of Health, NIDCR, Bethesda, USA) (Ohshima et al., [@B51]) and wildtype C57BL/6J mice (age 20-24 weeks) were inbred and housed under specific pathogen-free (SPF) conditions. For microarray expression profiling mice from the separate inbred colonies were used, whereas for RT-qPCR validation, α-Gal A^(−/0)^ mice backcrossed with wildtype C57BL/6J mice and wildtype C57BL/6J mice were used to control for inbred colony effects. Animals were maintained at constant room temperature of 24°C on a 12h light/dark cycle with lights on from 07:00 to 19:00 and had *ad libitum* access to autoclaved pelleted food and water. All animals were treated in accordance with the Ethics Guidelines of Animal Care (Medical University of Innsbruck), as well as the European Communities Council Directive of 22 September 2010 on the protection of animals used for scientific purposes (2010/63/EU), and approved by the Austrian National Animal Experiment Ethics Committee of the Austrian Bundesministerium für Wissenschaft und Forschung (permit number BMWF-66.011/0054-WF/V/3b/2015).

Tissue collection
-----------------

For microarray expression profiling four adult mice per group, and for RT-qPCR validation six adult mice per group were deeply anesthetized with isoflurane and euthanized by decapitation. Brains were removed, prefrontal cortices dissected and flash-frozen in liquid nitrogen. Samples were stored at −80°C until further processing.

Microarray expression profiling
-------------------------------

Genome-wide expression profiling was carried out by IMGM Laboratories (Munich, Germany) using Agilent SurePrint G3 Mouse GE 8x60K Microarrays in combination with a one-color based hybridization protocol. Microarray signals were detected using the Agilent DNA Microarray Scanner.

Total RNA including small RNAs was isolated using the miRNeasy Mini Kit (Qiagen) according to the manufacturer\'s instructions and eluted in 40 μl RNase-free water. RNA concentration and purity was determined on a NanoDrop ND-1000 spectral photometer (Peqlab). Samples were analyzed using the RNA 6000 Nano LabChip Kit (Agilent Technologies) on a 2100 Bioanalyzer (Agilent Technologies). For mRNA analysis, total RNA samples were spiked with *in vitro* synthesized polyadenylated transcripts (One-Color RNA Spike-In Mix, Agilent Technologies), reverse transcribed into cDNA and then converted into Cyanine-3 labeled complementary RNA (Low Input Quick-Amp Labeling Kit One-Color, Agilent Technologies) according to the manufacturer\'s instructions. cRNA concentration, RNA absorbance ratio and Cyanine-3 dye concentration were recorded using a NanoDrop ND-1000 UV-VIS spectral photometer, and quality of labeled cRNA was analyzed using the RNA 6000 Nano LabChip Kit (Agilent Technologies) on a 2100 Bioanalyzer (Agilent Technologies). Following cRNA clean-up and quantification, Cyanine-3-labeled cRNA samples were fragmented and prepared for one-color-based hybridization (Gene Expression Hybridization Kit, Agilent Technologies) and hybridized at 65^°^C for 17 h on Agilent SurePrint G3 Mouse GE 8x60K Microarrays. After hybridization, microarrays were washed with increasing stringency using Triton X-102 supplemented Gene Expression Wash Buffers (Agilent Technologies) followed by drying with acetonitrile (Sigma). Fluorescence signals were detected on an Agilent DNA Microarray Scanner and extracted using feature extraction software (Agilent Technologies). The data discussed in this publication have been deposited in NCBI\'s Gene Expression Omnibus (Edgar et al., [@B17]) and are accessible through GEO Series accession number GSE110645 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110645>).

RT-qPCR validation of regulated genes
-------------------------------------

Reverse transcription quantitative polymerase chain reaction (RT-qPCR) validation of regulated genes was performed using TaqMan Gene Expression Assays (Thermo Fisher Scientific) in an Applied Biosystems 7500 Fast Real-Time PCR System (Thermo Fisher Scientific).

Total RNA was extracted using peqGOLD TriFast reagent (Peqlab) according to the manufacturer\'s instructions. The quality and quantity of RNA was evaluated using NanoDrop 2000 (Thermo Scientific). Reverse transcription of mRNA was performed as previously described (Kummer et al., [@B40]). Genes of interest were analyzed by RT-qPCR using the following TaqMan Gene Expression Assays (Thermo Fisher Scientific): Mm00499982_m1 (Cdhr1), Mm01207095_g1 (Agfg2), Mm01297785_m1 (Cpne5), Mm00839582_m1 (Dynlt1a/1b/1c/1f), Mm00723335_m1 (Fam83a), Mm00619552_m1 (Fn3krp), Mm00446358_m1 (Fxyd2), Mm03646971_gH (Gm1987), Mm02391771_g1 (Hdac1), Mm01215650_m1 (Kcnj6), Mm01188211_m1 (S100pbp), Mm00555295_m1 (Sc5d), Mm00503605_m1 (Tmem25), Mm00836474_m1 (Zfp932), Mm00446968_m1 (Hprt), Mm01352363_m1 (Sdha), and Mm00441941_m1 (Tfrc). Experimental procedures were performed according to the TaqMan Gene Expression Assays protocol. The reactions were loaded on MicroAmp Fast Optical 96-well reaction plates (Thermo Fisher Scientific) and placed in the Applied Biosystems 7500 Fast Real-Time PCR System (Thermo Fisher Scientific). The PCR cycle protocol used was: 10 min at 95^°^C, 40 two-step cycles of 15 s at 95^°^C and 1 min at 60^°^C. Each sample was run in duplicates alongside non-template controls. Threshold was set manually at 0.1 and threshold cycle (C~T~) was used as a measure of initial RNA input. Relative fold changes in gene expression were calculated using the 2^−ΔΔ*CT*^ method. All fold changes were expressed relative to the respective expression in wildtype mice and analyzed using Welch\'s *t*-test. Three genes (i.e., Hprt, Sdha, and Tfrc) were used as reference genes. All three reference genes were found to be stably expressed in both groups of animals, as indicated by geNorm, Normfinder, and Bestkeeper software packages.

Bioinformatics analyses
-----------------------

GeneSpring GX 13.0 analysis software (Agilent Technologies) was used to normalize and analyze the microarray raw data. Data were normalized using non-parametric quantile normalization. Groups were compared using Welch\'s approximate *t*-test (unpaired unequal variances) and *p*-values corrected for multiple testing using the algorithm of Benjamini and Hochberg (Benjamini and Hochberg, [@B3]), controlling for false discovery rate (FDR). Differential expression between the two groups was determined by calculating fold changes of the averaged normalized expression values. Significantly regulated mRNAs were identified by applying filters on fold changes (absolute fold change ≥ 1.2 or ≥ 2) and p-values (*p* ≤ 0.01). Gene expression data were further processed by *R statistics* statistical software package (R Development Core Team, [@B59]) and Volcano plots prepared using R statistics *ggplot* library. Only genes with uncompromised hybridization values in all individual samples were used for the current analysis.

Protein-protein interaction analysis
------------------------------------

Protein-protein interactions were investigated for the significantly regulated mRNAs using the STRING Database v. 10.5 (<http://www.string-db.org>) (Szklarczyk et al., [@B66]), which includes direct and indirect protein associations collected from different databases. Interaction networks were prepared using medium confidence scores (0.40) and clustered using MCL clustering algorithm (inflation parameter: 3). Disconnected nodes were hidden from the network.

Functional enrichment and pathway analyses
------------------------------------------

Functional enrichment and pathway analyses were also performed using the STRING Database v. 10.5 (<http://www.string-db.org>). Classification systems tested were Gene Ontology and KEGG functional annotation spaces, employing Fisher\'s exact test followed by FDR correction for multiple testing. Only enriched pathways with FDR corrected *p*-values \< 0.05 are reported.

Results {#s3}
=======

mRNA expression profile of fabry mouse PFC
------------------------------------------

Using microarray expression profiling we found that in total 381 genes from the overall 21′393 detected mRNAs were significantly different between PFC samples from wildtype and α-Gal A^(−/0)^ mice (criteria *p* ≤ 0.01, absolute fold change ≥ 1.2) (Figure [1](#F1){ref-type="fig"}). Of those, 135 genes were significantly upregulated and 246 genes were significantly downregulated as compared to wildtype controls. More stringent filtering (criteria *p* ≤ 0.01, absolute fold change ≥ 2) of the significantly regulated genes revealed an assessable number of 50 genes in total (Figure [2](#F2){ref-type="fig"}). Using these criteria 19 genes were significantly upregulated, of which 11 showed FDR corrected *p* ≤ 0.1 (Table [1](#T1){ref-type="table"}). Furthermore, 31 genes were significantly downregulated, of which 17 showed FDR corrected *p* ≤ 0.1 (Table [2](#T2){ref-type="table"}). Protein-protein interaction (PPI) analysis (STRING Database) did not reveal clusters of interacting proteins or enriched pathways when applying the stringent filtering criteria, due to the low number of input genes. Therefore, less stringent filtering criteria (criteria *p* ≤ 0.01, absolute fold change ≥ 1.2) were used for PPI and enrichment analyses.

![Volcano plot of microarray data. Green color, *p* ≤ 0.01, fold change ≥ 1.2; labels, *p* ≤ 0.01, fold change ≥ 2.0; dot size represents relative expression values of wildtype mice.](fnmol-11-00201-g0001){#F1}

![Heatmap of significantly regulated genes. Cut-off values, *p* ≤ 0.01, fold change ≥ 2.](fnmol-11-00201-g0002){#F2}

###### 

Raw expression values, fold changes, and statistical analysis for significantly *upregulated* genes.

  **NCBI refSeq ID**   **Gene symbol**   **Gene name**                                      **Chromosome and location**   **Expression α-Gal^(--/0)^**   **Expression wildtype**   **Fold change**   ***p*-value**   **FDR**
  -------------------- ----------------- -------------------------------------------------- ----------------------------- ------------------------------ ------------------------- ----------------- --------------- ---------
  NM_001081032         Gm8909            Predicted gene 8909                                Chr17: 36302361--36302302     225                            63                        4.0               \< 0.0001       0.0288
  NM_181420            Fn3krp            Fructosamine 3 kinase related protein              Chr11: 121292014--121292073   252                            82                        3.4               \< 0.0001       0.0141
  NM_052823            Fxyd2             FXYD domain-containing ion transport regulator 2   Chr9: 45218302--45218361      5394                           1830                      3.4               \< 0.0001       0.0077
  BC030396             Fam83a            Family with sequence similarity 83, member A       Chr15: 57827097--57827156     82                             27                        3.4               \< 0.0001       0.0439
  NM_052823            Fxyd2             FXYD domain-containing ion transport regulator 2   Chr9: 45218281--45218340      5702                           1948                      3.4               \< 0.0001       0.0050
  NM_130878            Cdhr1             Cadherin-related family member 1                   Chr14: 37891446--37891387     2986                           1034                      3.3               0.0033          0.2910
  DQ459435             Gm4924            Predicted gene 4924                                Chr10: 81863532--81863591     2454                           1076                      2.6               \< 0.0001       0.0135
  NM_001025208         LOC547349         MHC class I family member                          --                            103                            45                        2.5               0.0017          0.2337
  NM_023734            Pi16              Peptidase inhibitor 16                             Chr17: 29465784--29465843     367                            163                       2.5               0.0076          0.3873
  XR_105403            A930033H14Rik     RIKEN cDNA A930033H14 gene                         Chr10: 68672629--68672570     182                            87                        2.3               0.0014          0.2149
  NM_153166            Cpne5             Copine V                                           Chr17: 29293557--29293498     591                            291                       2.3               \< 0.0001       0.0827
  NM_001199948         Dynlt1f           Dynein light chain Tctex-type 1F                   Chr17: 6606983--6607042       5258                           2692                      2.3               0.0076          0.3873
  NM_001166630         Dynlt1c           Dynein light chain Tctex-type 1C                   Chr17: 6812527--6812586       7657                           4016                      2.2               0.0072          0.3839
  NR_003518            Pisd-ps3          Phosphatidylserine decarboxylase, pseudogene 3     Chr11: 003030755--003030814   3473                           1816                      2.2               0.0028          0.2815
  NM_010118            Egr2              Early growth response 2                            Chr10: 67004798--67004857     546                            281                       2.2               0.0012          0.2052
  NR_040401            C920006O11Rik     RIKEN cDNA C920006O11 gene                         Chr9: 78026086--78026145      63                             33                        2.1               \< 0.0001       0.0510
  NM_145566            Agfg2             ArfGAP with FG repeats 2                           Chr5: 138104107--138104048    1041                           562                       2.1               \< 0.0001       0.0176
  NM_020576            Psors1c2          Psoriasis susceptibility 1 candidate 2 (human)     Chr17: 35671531--35671590     121                            66                        2.1               \< 0.0001       0.0906
  NM_023423            Akirin1           Akirin 1                                           Chr4: 123420761--123420702    1688                           945                       2.0               \< 0.0001       0.0283

*Genes with FDR-corrected p-values ≥ 0.1 are grayed out*.

###### 

Raw expression values, fold changes, and statistical analysis for significantly *downregulated* genes.

  **NCBI refSeq ID**   **Gene symbol**   **Gene name**                                                                   **Chromosome and location**    **Expression α-Gal^(--/0)^**   **Expression wildtype**   **Fold change**   ***p*-value**   **FDR**
  -------------------- ----------------- ------------------------------------------------------------------------------- ------------------------------ ------------------------------ ------------------------- ----------------- --------------- ---------
  NM_001193667         Gm1987            Predicted gene 1987                                                             chr4: 42232117-−42232176       263                            22237                     −74.4             \< 0.0001       0.0002
  NR_033506            Gm3893            Predicted gene 3893                                                             chrUn_random: 553693--553634   173                            3633                      −18.4             \< 0.0001       0.0050
  NM_001085530         Gm13298           Predicted gene 13298                                                            chr4: 41842107--41842166       455                            3557                      −6.8              \< 0.0001       0.0061
  NM_001085530         Gm13298           Predicted gene 13298                                                            chr4: 41841838-−41841897       491                            3682                      −6.5              \< 0.0001       0.0135
  NR_033506            Gm3893            Predicted gene 3893                                                             chrUn_random: 551587-−551528   182                            1003                      −4.9              \< 0.0001       0.0050
  NR_033123            4933409K07Rik     RIKEN cDNA 4933409K07 gene                                                      chr4: 42472710--42472769       566                            3139                      −4.8              \< 0.0001       0.0127
  NM_001085530         Gm13298           Predicted gene 13298                                                            chr4: 41841716--41841775       324                            1512                      −4.1              \< 0.0001       0.0050
  NM_001193666         Gm13304           Predicted gene 13304                                                            chr4: 41775274--41775333       9111                           36638                     −3.5              0.0003          0.1037
  NM_008228            Hdac1             Histone deacetylase 1                                                           chr4: 129193586--129193527     551                            2160                      −3.4              0.0003          0.1053
  NM_001025585         Kcnj6             Potassium inwardly-rectifying channel, subfamily J, member 6                    chr16: 95054032--95053973      91                             322                       −3.2              \< 0.0001       0.0050
  NM_133984            Hemk1             HemK methyltransferase family member 1                                          chr9: 107233482--107233423     70                             247                       −3.1              0.0035          0.2946
  NM_027865            Tmem25            Transmembrane protein 25                                                        chr9: 44602002--44601943       2483                           9033                      −3.1              \< 0.0001       0.0257
  NM_007536            Bcl2a1d           B cell leukemia/lymphoma 2 related protein A1d                                  chr9: 88618224--88618165       99                             340                       −3.1              0.0008          0.1665
  AK009987             2310058N22Rik     RIKEN cDNA 2310058N22 gene                                                      chr12: 117619193--117619252    1674                           5754                      −3.0              \< 0.0001       0.0135
  NM_029011            Pyroxd2           Pyridine nucleotide-disulphide oxidoreductase domain 2                          chr19: 42801304--42801245      70                             218                       −2.8              0.0010          0.1859
  NM_145563            Zfp932            Zinc finger protein 932                                                         chr5: 110439205--110439264     1479                           4497                      −2.6              0.0001          0.0361
  NM_008228            Hdac1             Histone deacetylase 1                                                           chr4: 129193775--129193716     154                            444                       −2.6              0.0057          0.3473
  NM_011338            Ccl9              Chemokine (C-C motif) ligand 9                                                  chr11: 83388282--83388223      78                             212                       −2.4              0.0028          0.2797
  NM_172803            Dock4             Dedicator of cytokinesis 4                                                      chr12: 41572977--41573036      2655                           7324                      −2.4              0.0037          0.2999
  NM_172769            Sc5d              Sterol-C5-desaturase (fungal ERG3, delta-5-desaturase) homolog (S. cerevisae)   chr9: 42062916--42062857       1191                           3202                      −2.3              \< 0.0001       0.0186
  AK139097             S100pbp           S100P binding protein                                                           chr4: 128854488--128854429     259                            670                       −2,3              \< 0.0001       0,0083
  NM_010399            H2-T9             Histocompatibility 2, T region locus 9                                          chr17: 36177230--36177171      90                             226                       −2.2              0.0002          0.0714
  NM_001135567         1190007I07Rik     RIKEN cDNA 1190007I07 gene                                                      chr10: 82082933--82082874      854                            2138                      −2.2              \< 0.0001       0.0050
  NM_022995            Pmepa1            Prostate transmembrane protein, androgen induced 1                              chr2: 173050025--173049966     2568                           6494                      −2.2              \< 0.0001       0.0051
  NM_018887            Cyp39a1           Cytochrome P450, family 39, subfamily a, polypeptide 1                          chr17: 43887735--43887794      225                            527                       −2.1              0.0004          0.1160
  NM_133721            Itga9             Integrin alpha 9                                                                chr9: 118807900--118807959     273                            637                       −2.1              0.0024          0.2622
  NM_009030            Rbbp4             Retinoblastoma binding protein 4                                                chr4: 128984682--128984623     149                            345                       −2.1              0.0001          0.0567
  NM_010395            H2-T10            Histocompatibility 2, T region locus 10                                         chr17: 36255977--36255918      87                             200                       −2.0              0.0056          0.3473
  NM_029104            Mss51             MSS51 mitochondrial translational activator                                     chr14: 21302782--21302415      104                            238                       −2.0              0.0008          0.1697
  NM_001005506         Txlna             Taxilin alpha                                                                   chr4: 129316603--129316544     80                             182                       −2.0              0.0041          0.3101
  NM_001085492         Rere              Arginine glutamic acid dipeptide (RE) repeats                                   chr4: 149882952--149883011     84                             190                       −2.0              0.0013          0.2103

RT-qPCR validation of regulated genes
-------------------------------------

We performed RT-qPCR analysis of the top 7 up- and downregulated genes in a separate set of PFC samples from α-Gal A^(−/0)^ mice backcrossed with C57BL/6J mice and control C57BL/6J wildtype mice, to validate the differentially expressed genes from the microarray expression profiling. One of the upregulated genes (i.e., Fam83a) had C~T~-values higher than 35 and was therefore excluded from further analysis. For the remaining upregulated genes, we validated that 3/6 genes (i.e., Fxyd2, Cdhr1, and Dynlt1a/1b/1c/1f) showed significant upregulation (Figure [3A](#F3){ref-type="fig"}, Supplementary Table [1](#SM1){ref-type="supplementary-material"}). Furthermore, 5/7 of the downregulated genes (i.e., Zfp932, Gm1987, Sc5d, Hdac1, and S100pbp) showed significant downregulation (Figure [3B](#F3){ref-type="fig"}, Supplementary Table [1](#SM1){ref-type="supplementary-material"}). Altogether, RT-qPCR validation yielded a verification rate of 62%.

![RT-qPCR validation of up- **(A)** and downregulated genes **(B)**. ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01.](fnmol-11-00201-g0003){#F3}

Enriched pathways and protein-protein interactions for upregulated mRNAs
------------------------------------------------------------------------

Performing enrichment analysis of the 135 upregulated genes neither revealed Gene Ontology processes, nor KEGG pathways. Also, PPI analysis of the significantly upregulated mRNAs revealed no significant PPI enrichment (*p* = 0.59; Figure [4](#F4){ref-type="fig"}).

![STRING database protein-protein interaction (PPI) networks of significantly *upregulated* genes. Cut-off values, *p* ≤ 0.01, fold change ≥ 1.2. Cluster analysis did not reveal any protein-protein interaction clusters.](fnmol-11-00201-g0004){#F4}

Enriched pathways and protein-protein interactions for downregulated mRNAs
--------------------------------------------------------------------------

Enrichment analysis of the 246 significantly downregulated genes revealed a number of regulated pathways, including immune related pathways (e.g., immune system process, immune/defense responses, regulation of cytokine production) and signaling pathways (e.g., regulation of cell communication, regulation of signaling, positive regulation of transport; Table [3](#T3){ref-type="table"}).

###### 

Enrichment-analysis for *downregulated* mRNAs in α-Gal^(−/0)^ vs. wildtype mice using Gene Ontology and KEGG pathway annotations.

  **Pathway ID**                  **Pathway description**                                                 **Count in network**   **False discovery rate**
  ------------------------------- ----------------------------------------------------------------------- ---------------------- --------------------------
  **BIOLOGICAL PROCESSES (GO)**                                                                                                  
  GO.0050789                      Regulation of biological process                                        94                     0.0382
  GO.0050794                      Regulation of cellular process                                          91                     0.0355
  GO.0048518                      Positive regulation of biological process                               61                     0.0466
  GO.0048583                      Regulation of response to stimulus                                      43                     0.0350
  GO.0051239                      Regulation of multicellular organismal process                          40                     0.0073
  GO.0010646                      Regulation of cell communication                                        39                     0.0355
  GO.0023051                      Regulation of signaling                                                 37                     0.0455
  GO.0002376                      Immune system process                                                   35                     \< 0.0001
  GO.0006955                      Immune response                                                         26                     \< 0.0001
  GO.0006952                      Defense response                                                        22                     0.0073
  GO.0040011                      Locomotion                                                              21                     0.0355
  GO.0051241                      Negative regulation of multicellular organismal process                 20                     0.0466
  GO.0051050                      Positive regulation of transport                                        19                     0.0355
  GO.0001817                      Regulation of cytokine production                                       17                     0.0014
  GO.0030155                      Regulation of cell adhesion                                             15                     0.0355
  GO.0045087                      Innate immune response                                                  14                     0.0073
  GO.0006935                      Chemotaxis                                                              13                     0.0244
  GO.0002252                      Immune effector process                                                 12                     0.0244
  GO.0007159                      Leukocyte cell-cell adhesion                                            10                     0.0423
  GO.0001818                      Negative regulation of cytokine production                              9                      0.0244
  GO.2000249                      Regulation of actin cytoskeleton reorganization                         4                      0.0438
  GO.0032606                      Type I interferon production                                            3                      0.0355
  GO.0002880                      Regulation of chronic inflammatory response to non-antigenic stimulus   2                      0.0466

*Whole genome was used as statistical background*.

In addition, the PPI analysis of significantly downregulated mRNAs showed a significant PPI enrichment (*p* \< 0.0001; Figure [5](#F5){ref-type="fig"}). The number of actually observed edges (*n* = 187) exceeded the expected number of edges (*n* = 73) by 156%. When taking a closer look at the PPI network, three clusters of highly interconnected proteins became apparent. Enrichment analysis of these clusters showed that those genes were involved in different pathways (Table [4](#T4){ref-type="table"}). The blue and green clusters were related to the immune system (e.g., immune response---GO:0006955, interferon production---GO:0032479, cytokine production---GO:0001817), whereas the pink cluster was associated with DNA modification and gene expression (e.g., gene expression---GO:0010467, DNA binding---GO:0003677).

![STRING database protein-protein interaction (PPI) networks of significantly *downregulated* genes. Cut-off values, *p* ≤ 0.01, fold change ≥ 1.2. Cluster analysis revealed four clusters of interacting proteins, of which one (purple cluster) did not show significantly enriched pathways and processes.](fnmol-11-00201-g0005){#F5}

###### 

GO Biological processes and molecular functions of PPI-clusters from *downregulated* mRNAs in α-Gal^(−/0)^ vs. wildtype mice.

  **Pathway ID**      **Pathway description**                                         **Count in network**   **False discovery rate**
  ------------------- --------------------------------------------------------------- ---------------------- --------------------------
  **BLUE CLUSTER**                                                                                           
  GO:0002376          Immune system process                                           6                      0.0054
  GO:0006955          Immune response                                                 5                      0.0052
  GO:0006952          Defense response                                                5                      0.0074
  GO:0032479          Regulation of type I interferon production                      4                      \< 0.0001
  GO:0051607          Defense response to virus                                       4                      0.0006
  GO:0045087          Innate immune response                                          4                      0.0077
  GO:0032481          Positive regulation of type I interferon production             3                      0.0009
  GO:0032648          Regulation of interferon-beta production                        3                      0.0011
  GO:0032606          Type I interferon production                                    2                      0.0054
  GO:0032728          Positive regulation of interferon-beta production               2                      0.0416
  **GREEN CLUSTER**                                                                                          
  GO:0002376          Immune system process                                           7                      0.0069
  GO:0032879          Regulation of localization                                      7                      0.0155
  GO:0051049          Regulation of transport                                         6                      0.0246
  GO:0001817          Regulation of cytokine production                               5                      0.0069
  GO:1903530          Regulation of secretion by cell                                 5                      0.0110
  GO:0006955          Immune response                                                 5                      0.0155
  GO:0051050          Positive regulation of transport                                5                      0.0239
  GO:0001819          Positive regulation of cytokine production                      4                      0.0155
  GO:0006935          Chemotaxis                                                      4                      0.0239
  GO:0050707          Regulation of cytokine secretion                                3                      0.0239
  **PINK CLUSTER**                                                                                           
  GO:0006351          Transcription, DNA-templated                                    7                      0.0007
  GO:0006355          Regulation of transcription, DNA-templated                      7                      0.0018
  GO:0010467          Gene expression                                                 7                      0.0027
  GO:0003677          DNA binding                                                     6                      0.0062
  GO:0006357          Regulation of transcription from RNA polymerase II promoter     5                      0.0202
  GO:0043565          Sequence-specific DNA binding                                   5                      0.0061
  GO:0006338          Chromatin remodeling                                            4                      0.0005
  GO:0051276          Chromosome organization                                         4                      0.0190
  GO:0000976          Transcription Regulatory Region Sequence-Specific DNA binding   4                      0.0193
  GO:0042826          Histone deacetylase binding                                     3                      0.0061
  GO:0000183          Chromatin silencing at rDNA                                     2                      0.0140
  GO:0043044          ATP-dependent chromatin remodeling                              2                      0.0221
  GO:0001106          RNA polymerase II transcription corepressor activity            2                      0.0223

Regulation of ion channels, receptors, and signaling proteins
-------------------------------------------------------------

To link the cognitive deficits associated with FD to an impairment of cortical neuron function, we specifically screened the microarray dataset for genes related to ion channels, receptors, synapse and signaling proteins. We found that two potassium channels (i.e., Kcnj13 and Kcnj6), as well as the neuropeptide S (Npsr1) and adenosine A2b receptors (Adora2b) were downregulated (Supplementary Table [2](#SM1){ref-type="supplementary-material"}). Validation of some of these differentially expressed genes was, however, problematic possibly due to dilution of neuronally expressed genes by genes from glial or other cell types. The delta chemokine receptor Cx3cr1 was also downregulated. Further, we found that ten different receptor tyrosine kinases (e.g., Il1rap, Il3ra, etc.) and protein tyrosine phosphatases (i.e., Ptprb and Ptprg) were downregulated. Furthermore, a number of synapse and signaling proteins were downregulated in the screen. The mRNA levels of the synaptic proteins Synaptoporin (Synpr), Synaptojanin 2 (Synj2), the active zone protein Rims1 and Snap25, as well as the signaling proteins RAS protein activator Rasal3 and the G-protein signaling modulator Gpsm3 were decreased.

In contrast, the nicotinic acetylcholine receptor α-subunit 4 and the low-density lipoprotein receptor sortillin-related receptor (Sorl1) were upregulated in our screen, as were the toll-interleukin 1 receptor domain-containing adaptor protein (Tirap), the mitogen-activated proteins Mapk8 and Mapk1ip1l, and the G-protein Gng7. These findings suggest that indeed functional changes occur in the brain as a consequence of α-Gal A depletion which, may affect synaptic signaling and information processing in cortical circuits.

Discussion {#s4}
==========

FD patients exhibit small fiber neuropathy with pain symptoms already in early childhood, which are thought to arise from accumulation of the glycolipid Gb3 specifically in DRG neurons and peripheral nerves (Kocen and Thomas, [@B38]; Ohnishi and Dyck, [@B50]; Bangari et al., [@B2]; Godel et al., [@B25]). However, neuronal accumulation of Gb3 not only occurs in DRGs and peripheral nerves, but also in central nervous system tissues, like the spinal cord, medulla oblongata, hypothalamus, amygdala, substantia nigra, raphe nuclei, hippocampus, and cortical layers 5/6 (de Veber et al., [@B16]; Itoh et al., [@B34]; Khanna et al., [@B37]; Tuttolomondo et al., [@B70],[@B71]). Besides accumulation in neurons, glycolipid deposits are also found in the walls of cerebral vessels, leading to occlusion of blood vessels with malperfusion of different brain areas (Tagliavini et al., [@B67]; Itoh et al., [@B34]; Reisin et al., [@B60]; Tuttolomondo et al., [@B70]), acute ischemia and stroke (Fazekas et al., [@B20]), microstructural damage and white matter lesions (Fellgiebel et al., [@B21]; Paavilainen et al., [@B53]; Sigmundsdottir et al., [@B64]; Underhill et al., [@B72]). Even mutations in the GLA gene that were considered asymptomatic are associated with neuronal damage (Lenders et al., [@B42]).

In line with these findings, cognitive deficits frequently occur in FD patients: Besides decreased health-related quality of life, which itself already constitutes a debilitating factor for affected patients, an increased risk for depression, anxiety, acute psychotic symptoms, as well as personality and behavioral changes is associated with FD (Bolsover et al., [@B8]). In addition, deficits in general intellectual functioning, speed of information processing, reasoning, verbal fluency and problem solving are frequent (Sigmundsdottir et al., [@B64]), whereas alterations of memory and attentional performance are controversially discussed: While in a study of Sigmundsdottir et al. ([@B64]) no differences in memory and attention are reported, Schermuly et al. ([@B63]) present evidence for deficits in the attention domain, as well as learning and memory deficits that correlate with the extent of white matter lesions. Also, FD patients can develop progressive and significant hippocampal volume loss over an 8-year observation period (Lelieveld et al., [@B41]).

Based on these studies on the involvement of circuits responsible for attention and executive function, we for the first time investigated differences in mRNA expression in the PFC of a well-accepted FD mouse model \[α-Gal A^(−/0)^\]. An FD specific gene expression profile was discovered in murine brain samples with 381 differentially expressed genes. Of those, 135 genes were significantly up-, and 246 were significantly downregulated. Involved pathways comprised mainly immune system processes, cytokine production and cell signaling. This finding correlates well with previous studies in humans, showing that lysosomal storage disorders, and particularly FD, are associated with deficits in innate and adaptive immunity (Daly et al., [@B13]; Hawkins-Salsbury et al., [@B28]; Mauhin et al., [@B48]). Especially the downregulated genes in the green and blue clusters were associated with immune system related pathways (Table [4](#T4){ref-type="table"}). Interestingly, age-related cognitive decline is associated with exacerbated neuroinflammatory responses in the aging brain (David et al., [@B14]; Viviani and Boraso, [@B73]; Corona et al., [@B12]; Farso et al., [@B19]; Xie et al., [@B76]), and the brains from aged animals show increased cytokine and chemokine levels (Bodles and Barger, [@B6]; Lynch et al., [@B46]). These might be caused by activated microglia, which constitute the major source of inflammatory cytokines and chemokines in the central nervous system (Hanisch and Kettenmann, [@B26]; Kettenmann et al., [@B36]). So far, however, microglia involvement has not been systematically explored in FD.

Another cluster that emerged in our analysis was associated with DNA binding, chromatin remodeling and gene expression (Table [4](#T4){ref-type="table"}, pink cluster). Several studies show that lysosomal storage disorders are associated with epigenetic changes (Hassan et al., [@B27]). Differential methylation patterns and decreased expression of DNA methyltransferase 3a are found in cerebellar neurons of a mouse model for presymptomatic Niemann-Pick type C disease (Kennedy et al., [@B35]) and Hubner et al. ([@B33]) provide the only report on alteration of calcitonin receptor promotor methylation in FD patients on enzyme replacement therapy. Histone modifications as well as the efficacy of HDAC inhibitors have been investigated for Niemann-Pick type C (Helquist et al., [@B30]) and Gaucher disease (Lu et al., [@B43]). Regarding FD, evidence is available from transgenic mouse fibroblasts overexpressing a human α-Gal A mutation that HDAC inhibition rescues α-Gal A trafficking blockade, but without an effect on lysosomal Gb3 storage (Yam et al., [@B78]). Finally, another possibility of regulating gene expression is through non-coding RNAs, particularly microRNAs, and dysregulation of microRNAs occurs in the Niemann-Pick type C as well as Gaucher type lysosomal storage disorders (Queiroz et al., [@B58]). However, respective knowledge on microRNA dysregulation in FD is unavailable to date.

Regarding the cognitive deficits, several ion channels, such as Kcnj13 or Kcnj6, and ion channel modulators were deregulated in the present screen. Some of them, e.g., Kir7.1 (Kcnj13) are critically involved in setting neuronal excitability and firing activity (Ghamari-Langroudi et al., [@B24]). G protein-coupled inwardly rectifying potassium (GIRK/Kir3) channels such as Girk2 (Kcnj6) are key effectors in inhibitory signaling pathways. GIRK-dependent signaling contributes to pain perception, reward-related behavior, mood, cognition and addiction (Lujan et al., [@B44]). In particular, several Kcnj6 "pain risk" alleles are known to date (Bruehl et al., [@B9]), and neuroprotective roles of GIRK channels are emerging (Sanchez-Rodriguez et al., [@B62]), supporting a potential contribution of Kcnj6 downregulation in the cognitive decline of FD patients with age.

Few of the significantly regulated genes discovered in the present study are associated with aging- or disease-related pathophysiological changes: Neuropeptide S modulates arousal and produces anxiolytic-like effects (Xu et al., [@B77]; Okamura and Reinscheid, [@B52]), therefore the downregulation of neuropeptide S receptor (Npsr1) found in the current screen could be linked to the increased anxiety-like behavior found in FD mice (Hofmann et al., [@B31]). The Interferon alpha/beta receptor Ifnar1 is associated with sickness behavior and cognitive dysfunction, which frequently occurs upon Type 1 Interferon treatment in humans and in patients with autoimmune disorders (Blank et al., [@B5]), and lack of Ifnar1 causes Lewy Body- and Parkinson\'s disease-like dementia (Ejlerskov et al., [@B18]). The histone-binding protein Rbbp4, which was downregulated in our screen, is involved in age-related memory loss, and inhibition of this gene causes hippocampus dependent memory deficits in young mice (Pavlopoulos et al., [@B56]). Early life stress leads to decreased HDAC1 levels targeting promoters of plasticity-associated genes, e.g., the transcription factor Egr2, while at the same time triggering persistent impairment in working memory and attention (Adler and Schmauss, [@B1]). Neuronal expression of the protein tyrosine phosphatase Ptprb is involved in neurito- and synaptogenesis (Hayashi et al., [@B29]), and Interleukin 1 modulates hippocampal neuron function by potentiation of NMDA-induced calcium influx (Huang et al., [@B32]). The lysosomal cysteine proteinase Ctss and the high affinity IgE receptor gamma subunit Fcer1g, which were both downregulated in the current study, are associated with Alzheimer\'s disease (AD), and in particular, Fcer1g is considered as a risk factor for AD (Taguchi et al., [@B69]; Castillo et al., [@B10]). Ctss is also related to amyotrophic lateral sclerosis (ALS) (Berjaoui et al., [@B4]). Although ALS represents a neurodegenerative disorder that predominantly affects the motor system, cognitive decline and behavioral symptoms occur in ALS patients (Phukan et al., [@B57]), and mutations in Macrophage colony-stimulation factor 1 receptor (Csf1r), a gene that interacts with both Ctss and Fcer1g, causes axonal spheroids as a sign of Wallerian degeneration (Lynch et al., [@B47]). Csf1r, which was downregulated in our screen, facilitates protection and survival of uninjured neurons in the hippocampus and cortex (Luo et al., [@B45]), and Csf1r signaling via administration of Csf1 ameliorates memory deficits in an Alzheimer\'s disease mouse model (Boissonneault et al., [@B7]). Finally, Interleukin 3 has been shown to protect cortical neurons from neurodegeneration (Zambrano et al., [@B79]). Thus, our findings support the idea that neurodegeneration may constitute a so far neglected entity of FD pathology in the peripheral and the central nervous system.

Interestingly, significantly regulated genes in the current screen were to a large extent similar to those from our recently published gene expression analysis of α-Gal A^(−/0)^ mouse DRGs (Kummer et al., [@B40]). Similar to DRGs, immune system related pathways (e.g., "immune response", "defense response", etc.) were overrepresented. Also, the most differentially expressed genes (i.e., Pmepa1, S100pbp, Tmem25, Hdac1, Zfp932, Pyroxd2, Dynlt1c, Dynlt1f) as well as predicted genes (i.e., Gm1987, Gm3893, Gm13298, 4933409K07Rik, 2310058N22Rik, 1190007I07Rik, A930033H14Rik) were strongly regulated in both PFC and DRG samples. Altogether, 113 individual genes were significantly regulated in both neuronal tissue types, suggesting a pan-neuronal effect that might be a hallmark and the underlying cause of neuron abnormalities leading to changes in excitability and signal transduction in FD.

Particularly strenuous for FD patients are the pain attacks they experience already in adolescence (Germain, [@B23]). In addition to the altered gene expression in DRGs, gene expression changes in relevant brain areas may play a critically important part in the development of the FD pain phenotype. Both prefrontal and sensory cortices, but also insular cortex and basal ganglia circuits are actively involved in the perception of chronic neuropathic pain (Xie et al., [@B75]), and white matter lesions affecting projections to these brain regions are likely involved in the amplified pain perception of FD patients. Irrespective of whether the cognitive deficits in FD are directly caused by a neuronal dysfunction due to changes in gene expression and regulation, or if they are caused indirectly by deficits in blood supply of specific brain regions, they constitute an important clinical problem.

Different limitations have to be considered when evaluating the current data analysis. Although the α-Gal A^(−/0)^ mouse model closely resembles the underlying genetics of FD patients, alternative FD mouse models have been developed, as for example the G3Stg/GLA^(−/−)^ mouse, which expresses human Gb3 synthase (Taguchi et al., [@B68]), or the NOD/SCID immune deficiency mouse that also shows tissue specific Gb3 accumulation, although without clinical manifestation (Pacienza et al., [@B54]). It would be important to investigate if similar genes and pathways are affected in those mouse models. Also, the general moderate statistical power of gene expression screens due to the low number of tested cases---in the current experiment four per group---should be considered. Although the genotype of inbred genetically modified mouse lines can be assumed to be similar, genetic variations between individuals can exist. When performing gene expression screens in small cohorts, the probability of false positive results is high, due to the large number of multiple comparisons performed for all genes tested. Therefore, different methods of FDR (false discovery rate) corrections have been introduced for large scale genetic studies. These FDR corrections drastically reduce the number of false positively reported changed genes, but on the other hand dramatically increase the number of false negatives (Park and Mori, [@B55]). As a result, genes that are actually differentially expressed might be judged as not being significantly changed, and therefore might be disregarded in subsequent validation experiments. Exceedingly stringent correction of gene expression analysis over-emphasizes true positive genes and shifts the results toward a true-positive/false-negative bias. The presented analysis was designed to nevertheless provide a weighed analysis, neither overestimating false-positives, nor false-negatives, due to the moderate stringency applied.

In the present screen we make use of a genetic FD mouse model to provide first knowledge on gene expression signatures and pathways other than Gb3 accumulation in central nervous system neuronal tissue that may be involved in FD pathogenesis.
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